XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)
$ in Thousands
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration payable $ 27,317 $ 25,825
Level 3    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration payable 27,317 $ 25,825
Callidus Biopharma Inc | Clinical and regulatory milestones | ATB200 Pompe Program    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration payable $ 25,914  
Callidus Biopharma Inc | Clinical and regulatory milestones | Probability of achievement of milestones | ATB200 Pompe Program | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 0.75  
Callidus Biopharma Inc | Clinical and regulatory milestones | Probability of achievement of milestones | ATB200 Pompe Program | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 0.78  
Callidus Biopharma Inc | Clinical and regulatory milestones | Level 3 | Discount rate | ATB200 Pompe Program | Probability weighted discounted cash flow    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 0.075